ML-CDSS

Uses

How it works

Benefits

Background

Evidence quality

Highlighted claims

• The ML-CDSS was developed through a collaboration between UCL, Durham University, and Evergreen Life, with the ML model built by the universities and the web platform by Evergreen Life. — What are the views of cancer care administrators and clinicians in England on the use of a machine learning clinical decision support system (ML-CDSS) to predict patients’ risk of hepatic and renal deterioration during chemotherapy? A qualitative study
• The ML-CDSS analyses blood chemistry data specifically from treatment cycles three and four to generate risk predictions. — What are the views of cancer care administrators and clinicians in England on the use of a machine learning clinical decision support system (ML-CDSS) to predict patients’ risk of hepatic and renal deterioration during chemotherapy? A qualitative study
• The ML-CDSS was designed for use with chemotherapy regimens that treat breast, colorectal, and lymphoma cancers. — What are the views of cancer care administrators and clinicians in England on the use of a machine learning clinical decision support system (ML-CDSS) to predict patients’ risk of hepatic and renal deterioration during chemotherapy? A qualitative study
• The two intended clinical outputs of the ML-CDSS are reducing blood test frequency for lower-risk patients and enabling enhanced monitoring for higher-risk patients. — What are the views of cancer care administrators and clinicians in England on the use of a machine learning clinical decision support system (ML-CDSS) to predict patients’ risk of hepatic and renal deterioration during chemotherapy? A qualitative study
• The ML-CDSS was not in active clinical use at any participating site at the time of the study, so all findings are based on hypothetical discussion rather than observed practice. — What are the views of cancer care administrators and clinicians in England on the use of a machine learning clinical decision support system (ML-CDSS) to predict patients’ risk of hepatic and renal deterioration during chemotherapy? A qualitative study
• The ML-CDSS was perceived as potentially mitigating laboratory delays by reducing the total number of blood tests required. — What are the views of cancer care administrators and clinicians in England on the use of a machine learning clinical decision support system (ML-CDSS) to predict patients’ risk of hepatic and renal deterioration during chemotherapy? A qualitative study
• Participants believed the ML-CDSS could improve blood result triaging, reduce unnecessary hospital visits, cut treatment delays, reduce drug and resource waste, and lower overall NHS costs. — What are the views of cancer care administrators and clinicians in England on the use of a machine learning clinical decision support system (ML-CDSS) to predict patients’ risk of hepatic and renal deterioration during chemotherapy? A qualitative study